Congratulations to Adam Chisholm for his recognition in Benchmark Litigation's 40 & Under Hot List! 

news & knowledge 

August 2020

Benchmark Litigation has recognized Adam Chisholm as one of Canada's leading litigators in their 2020 40 & Under Hot List. This exclusive list commemorates the most notable up-and-coming litigation lawyers in Canada based on recent case work, peer review and client feedback.

Each year, the Benchmark team sets out to find the best and brightest lawyers who stand out in their practices throughout the US and in Canada. The current group of litigators is diverse and enthusiastic, ready to take the reins from previous generations. These young ambitious and accomplished lawyers frequently handle major cases – some of which are high-stakes or precedent-setting.

Adam's practice focuses on litigating intellectual property, securities and administrative law/regulatory matters. Clients and colleagues consistently praise Adam’s substantive legal knowledge and technical skills. He thrives on complexity and is never afraid to propose bold, novel solutions, in many cases breaking new ground in the industry.

Some of the recent landmark cases Adam has been involved in include:

  • Lead counsel representing the directors and officers of Sino-Forest Corporation at the Ontario Securities Commission, Divisional Court, Court of Appeal and seeking leave to the Supreme Court of Canada.
  • Lead litigation counsel for The Catalyst Capital Group Inc. in its successful challenge to the disclosure in a take-private transaction for Hudson's Bay Company, one of 2019/2020's most significant securities hearings. The Ontario Securities Commission prevented the transaction until public disclosure was corrected.
  • Acting for a major sports league with respect to a dispute involving the interplay between trademark and human rights legislation.

Adam had the opportunity to speak to Benchmark Editor Michael Rafalowich about his unique practice, a recent victory and how to pay it forward.  Click here for the exclusive Q&A.